Zai Lab presented updated Phase 1 data for ZL-1310, an investigational DLL3-targeted antibody-drug conjugate (ADC) for ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Xcelerate has unveiled the bioX Genetics Platform, which cuts the time needed to detect genetic variants by 98% and achieves ...

The new data from the PERSEUS and CEPHEUS studies show that DARZALEX FASPRO®-based regimens achieve up to 95% 4-year PFS and over 55% sustained MRD negativity in transplant-eligible patients, and 69% ...

V Foundation and Cancer Vaccine Coalition Partner to Accelerate Breast Cancer Vaccine ...

The results from ATOMIC trial, presented at ASCO 2025, show that adding atezolizumab (Tecentriq) to FOLFOX chemotherapy ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high ...

Presented at ASCO 2025, new post-hoc analyses from the Phase III ARANOTE trial showed that darolutamide (Nubeqa) plus ADT ...